Skip to content

Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery

Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Graft Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01247545
Acronym
ERICCA
Enrollment
1612
Registered
2010-11-24
Start date
2010-11-30
Completion date
2015-03-31
Last updated
2015-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

Remote ischemic preconditioning, Coronary artery bypass graft surgery, Cardioprotection, Clinical Outcomes

Brief summary

Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths (2006) and costing the UK economy over £7.9 billion a year. Patients with severe CHD are usually treated by coronary artery bypass graft (CABG) surgery, the risks of which are increasing due to older and sicker patients being operated on. New treatment strategies are therefore required to improve health outcomes in these high-risk patients undergoing CABG with or without valve (CABG±valve) surgery. The hypothesis tested in this research proposal is that remote ischaemic preconditioning (RIC), a virtually cost-free, non-pharmacological and simple non-invasive strategy for reducing the damage to the heart muscle at the time of surgery, improves health outcomes in high-risk patients undergoing CABG±valve surgery. In this research project, 1610 high-risk patients undergoing CABG±valve surgery will be recruited via 28 UK hospitals performing heart surgery. Patients will be randomly allocated to receive either RIC or control. For RIC, a blood pressure cuff will be placed on the upper arm to temporarily deprive it of oxygen and nutrients, an intervention which has been shown in the investigators pilot studies to reduce damage to the heart muscle by up to 40% during CABG±valve surgery. The investigators will determine whether RIC can improve health outcomes in terms of better patient survival, less heart attacks and strokes, shorter hospital stay; less damage to the heart, kidney and brain during surgery; better heart function post-surgery and less chance of developing heart failure; better exercise tolerance and quality of life.

Interventions

Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.

PROCEDUREControl

Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.

Sponsors

University College, London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing CABG with or without valve surgery using blood cardioplegia 2. Patients aged 18 years and above 3. Patients with an additive Euroscore greater than or equal to 5

Exclusion criteria

1. Cardiogenic shock 2. Cardiac arrest on current admission 3. Pregnancy 4. Significant peripheral arterial disease affecting the upper limbs 5. Patients with significant hepatic dysfunction (Prothrombin\>2.0 ratio) 6. Patients with significant pulmonary disease (FEV1\<40% predicted) 7. Patients with known renal failure with a GFR\<30 mL/min/1.73 m2 8. Patients on glibenclamide or nicorandil, as these medications may interfere with RIC 9. Patients recruited into another study which may impact on the ERICCA study

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiac and cerebral eventsOne year post-surgeryCombined endpoint of Cardiovascular death, MI, Revascularisation and Stroke.

Secondary

MeasureTime frameDescription
30 day MACCE30 days post surgeryMajor adverse cardiac and cerebral events 30 days post surgery
All cause death1 year post surgery
Peri-operative myocardial injury72 hours peri-operative period72 hours area under curve serum troponin-T
LV ejection fractionAt one yearEcho determined LV ejection fraction
Acute kidney injuryPeri-operativeAcute kidney injury score and 24 hour area under curve serum NGAL
Length of hospital stayUntil hospital discharge
Inotrope score72 hours post surgeryInotrope score after 72 hours
6 minute Walk Test6 weeks and 12 months post surgery
Quality of Life6 weeks, 3/6/9 and 12 months post surgeryQuality of Life assessed using the EQ-5D measurement
Length of ITU stayITU stay

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026